Publications
- Ocrelizumab in the treatment of multiple sclerosis - view of a neurologist and immunologist2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later2016 | First Faculty of Medicine
- Pediatric multiple sclerosis : up-to date summary and case-report2014 | First Faculty of Medicine
- Interferon beta in the current treatment of multiple sclerosis2013 | First Faculty of Medicine
- Treatment intramuscular interferon beta-1a2013 | First Faculty of Medicine
- Interferon beta and the state of the art in treatment of relapsing-remitting multiple sclerosis +12007 | First Faculty of Medicine
- Interferon beta and the state of the art in treatment of relapsing-remitting multiple sclerosis2007 | Publication without faculty affiliation
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | First Faculty of Medicine, Third Faculty of Medicine
- To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection2022 | First Faculty of Medicine
- Neurology2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Second Faculty of Medicine, Central Library of Charles University
Loading network view...